Species-crossreactive scFv against the tumor stroma marker "Fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse

被引:49
作者
Brocks, B
Garin-Chesa, P
Behrle, E
Park, JE
Rettig, WJ
Pfizenmaier, K
Moosmayer, D
机构
[1] Univ Stuttgart, Inst Zellbiol & Immunol, D-70569 Stuttgart, Germany
[2] Boehringer Ingelheim KG, Pharma, Biberach, Riss, Germany
关键词
D O I
10.1007/BF03401851
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Fibroblast activation protein (FAP) is a type II membrane protein expressed on tumor stroma fibroblasts in more than 90% of all carcinomas. FAP serves as a diagnostic marker and is potential therapeutic target for treatment of a wide variety of FAP(+) carcinomas. Murine tumor stroma models and FAP-specific antibodies are required to investigate the functional role of FAP in tumor biology and its usefulness for drug targeting. We here describe the development of antibodies with crossreactivity for human (hFAP) and murine FAP (mFAP), which share 89% amino acid identity. Material and Methods: An FAP(-/-) mouse was sequentially immunized with recombinant murine and human FAP-CD8 fusion proteins. Immunoglobulin cDNA derived from hyperimmune spleen cells was used for the construction of a combinatorial single chain Fv (scFv) library. Phage display selection of FAP-specific scFv was performed on immobilized hFAP followed by selection on cells expressing murine FAR Results: High-affinity, species-crossreactive, FAP-specific scFv were isolated upon sequential phage display selection. A bivalent derivative (minibody MO36) constructed thereof was applied for immunohistochemical analyses and allowed detection of FAP expression on stroma cells of different human carcinomas as well as on murine host stroma in a tumor xenograft model. Conclusions: MB MO36, derived from phage display selected species crossreactive scFv, is suitable for tumor stroma targeting and will be a valuable tool in the analyses of the functional role of FAP in tumor biology as well as in the evaluation of the suitability of FAP for drug targeting.
引用
收藏
页码:461 / 469
页数:9
相关论文
共 35 条
[1]  
AMES RS, 1995, J IMMUNOL, V154, P6355
[2]   Cancer research - Designing therapies that target tumor blood vessels [J].
Barinaga, M .
SCIENCE, 1997, 275 (5299) :482-484
[3]  
Brinkmann U, 2000, IN VIVO, V14, P21
[4]   Engineering antibodies for imaging and therapy [J].
Carter, P ;
Merchant, AM .
CURRENT OPINION IN BIOTECHNOLOGY, 1997, 8 (04) :449-454
[5]  
DATMAJUMDAR AK, 1996, IMMUNOGEMETICS, V43, P141
[6]   ISOLATION OF IGG ANTIBODY FV-DNA FROM VARIOUS MOUSE AND RAT HYBRIDOMA CELL-LINES USING THE POLYMERASE CHAIN-REACTION WITH A SIMPLE SET OF PRIMERS [J].
DUBEL, S ;
BREITLING, F ;
FUCHS, P ;
ZEWE, M ;
GOTTER, S ;
WELSCHOF, M ;
MOLDENHAUER, G ;
LITTLE, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 1994, 175 (01) :89-95
[7]   MEASUREMENTS OF THE TRUE AFFINITY CONSTANT IN SOLUTION OF ANTIGEN-ANTIBODY COMPLEXES BY ENZYME-LINKED IMMUNOSORBENT-ASSAY [J].
FRIGUET, B ;
CHAFFOTTE, AF ;
DJAVADIOHANIANCE, L ;
GOLDBERG, ME .
JOURNAL OF IMMUNOLOGICAL METHODS, 1985, 77 (02) :305-319
[8]   CELL-SURFACE GLYCOPROTEIN OF REACTIVE STROMAL FIBROBLASTS AS A POTENTIAL ANTIBODY TARGET IN HUMAN EPITHELIAL CANCERS [J].
GARINCHESA, P ;
OLD, LJ ;
RETTIG, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (18) :7235-7239
[9]   Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [J].
Hanahan, D ;
Folkman, J .
CELL, 1996, 86 (03) :353-364
[10]   Antibody engineering [J].
Hayden, MS ;
Gilliland, LK ;
Ledbetter, JA .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (02) :201-212